Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gabriel Abreu

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
Modern Rheumatology|September 14, 2023
The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysisYoshiya Tanaka, Tatsuya Atsumi, Masato Okada, et al.
Modern Rheumatology|January 17, 2025
Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trialYoshiya Tanaka, Tatsuya Atsumi, Masato Okada, et al.
Annals of the Rheumatic Diseases|March 26, 2022
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trialsEdward M Vital, Joan T Merrill, Eric F Morand, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2022
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusKenneth C Kalunian, Richard Furie, Eric F Morand, et al.
The Neuroradiology Journal|June 13, 2025
Endovascular or microsurgical? Defining the best approach for blood blister aneurysms: A comparative meta-analysisFilipi Fim Andreão, Helvécio Neves Feitosa Filho, Emanuel Abrantes Barros, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
Modern Rheumatology|September 14, 2023
The long-term safety and tolerability of anifrolumab for patients with systemic lupus erythematosus in Japan: TULIP-LTE subgroup analysisYoshiya Tanaka, Tatsuya Atsumi, Masato Okada, et al.
Modern Rheumatology|January 17, 2025
Efficacy of anifrolumab in systemic lupus erythematosus patients with serological manifestations: A post hoc analysis of the Japan subgroup of the TULIP-2 trialYoshiya Tanaka, Tatsuya Atsumi, Masato Okada, et al.
Annals of the Rheumatic Diseases|March 26, 2022
Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trialsEdward M Vital, Joan T Merrill, Eric F Morand, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 12, 2022
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus ErythematosusKenneth C Kalunian, Richard Furie, Eric F Morand, et al.
The Neuroradiology Journal|June 13, 2025
Endovascular or microsurgical? Defining the best approach for blood blister aneurysms: A comparative meta-analysisFilipi Fim Andreão, Helvécio Neves Feitosa Filho, Emanuel Abrantes Barros, et al.
Pageof 3